Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers
Geleen, November 13th, 2025. Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced top line results from its phase 1 study evaluating the safety, tolerability & pharmacokinetics of a 120-hour intravenous (IV) continuous infusion with its lead compound M6229. The study met its primary objectives, showing […]